Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P442. Replication of susceptibility loci identified by genome-wide association studies for ulcerative colitis in Japanese population
P442

Outcome of early surgery versus aggresive medical therapy in patients with newly diagnosed limited inflammatory/obstructive (A2/3L1B1/2) terminal Ileitis: A two-year, prospective, single-center, pilot study

Authors:

G. Mantzaris*1, K. Papamichael1, I. Papakonstantinou2, D. Magganas3, I. Kalogeropoulos4, E. Archavlis1, A. Christidou1, H. Vienna1, N. Kyriakos1, X. Tzannetakou1, I. Internos1, S. Anastasiadis1, P. Karatzas1, L. Varytimiadis1

1Evangelismos Hospital, Gastroenterology Department, Athens, Greece, 2Aretaeion Hospital, B' Department of Surgery, Athens, Greece, 3Evangelismos Hospital, A' Department Of Surgery, Athens, Greece, 4Evangelismos Hospital, Radiology Department, Athens, Greece

P443.

Infliximab use during pregnancy in Crohn's disease

Authors:

J. Ramos, D. Carvalho, P. Russo, J. Saiote, G. Ramos, T. Bentes, Hospital Santo António dos Capuchos, Gastroenterology, Lisboa, Portugal

P443. ER stress in Paneth cells of inactive Crohn's disease patients with ATG16L1 mutations
P443. Local infliximab treatment followed by endoscopic dilation reduces ileocolonic anastomotic Crohn's disease recurrence
Authors:

M. Mastronardi1, P. Giorgio1, G. Di Matteo1, G. Sisto2, F. Pezzolla2, 1IRCCS “S. De Belllis”, Gastroenterology and Digestive Endoscopy, Castellana Grotte, Italy, 2IRCCS “S. De Belllis”, Chirurgia Gastroenterologica, Castellana Grotte, Italy

P443

Soluble TNF serum levels during the induction phase in Crohn's Disease patients with anti-TNF treatment

Authors:

M. Chaparro*1, I. Guerra2, M. Iborra3, J.L. Cabriada4, L. Bujanda5, C. Taxonera6, V. García-Sánchez7, I. Marín-Jiménez8, M. Barreiro de-Acosta9, I. Vera10, M.D. Martín-Arranz11, B. Hernández-Breijo12, F. Mesonero13, L. Sempere14, M.T. Arroyo15, M.D. Hinojosa16, M. Ramas1, A. Algaba2, B. Beltrán3, A. Rodríguez Pescador4, M.J. Perugorria5, J.L. Mendoza6, J.M. Benítez-Cantero7, L. Tardío8, R. Ferreiro9, V. Matallana Royo10, S. Gómez Senent11, L. Guijarro12, P.M. Linares1, J.P. Gisbert1

1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain, 3Hospital Universitario La Fe and CIBERehd, Gastroenterology Unit, Valencia, Spain, 4Hospital Galdakao, Gastroenterology Unit, Vizcaya, Spain, 5Hospital de Donostia, Instituto Biodonostia, UPV/EHU and CIBEREHD, Gastroenterology Unit, Guipuzcoa, Spain, 6Hospital Clínico Universitario San Carlos and IdISSC, Gastroenterology Unit, Madrid, Spain, 7Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 8Hospital General Universitario Gregorio Marañón, Gastroenterology Unit, Madrid, Spain, 9Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 10Hospital Universitario Puerta de Hierro , Gastroenterology Unit, Madrid, Spain, 11Hospital Universitario La Paz , Gastroenterology Unit, Madrid, Spain, 12Universidad de Alcalá and CIBERehd, Systems Biology, Alcalá de Henares, Spain, 13Hospital Universitario Ramón y Cajal, Gastroenterology Unit, Madrid, Spain, 14Hospital General Universitario de Alicante, Gastroenterology Unit, Alicante, Spain, 15Hospital Clínico Universitario Lozano Blesa and CIBERehd, Gastroenterology Unit, Zaragoza, Spain, 16Hospital de Manises, Gastroenterology Unit, Valencia, Spain

P444.

Infliximab trough levels and antibodies: relationship with infusion reaction, immunomodulators and biological parameters

Authors:

M.D. Martin Arranz1, E. Martin Arranz1, D. Pascual-Salcedo2, C. De Diego2, M. Jaquotot3, S. Gomez Senent1, J. Poza1, J.M. Suarez Parga1, 1Hospital Universitario La Paz, Gastroenterology, Madrid, Spain, 2Hospital Universitario La Paz, Immunology, Madrid, Spain, 3Rey Juan Carlos University Hospital, Gastroenterology, Madrid, Spain

P444. Candidate genes for azathioprine treatment response in inflammatory bowel disease patients using an exome-wide genotyping analysis
P444. Low-dose thiopurine and allopurinol co-therapy results in significant cost savings at a district general hospital
Authors:

H. Johnson1, H. Dewhurst1, S. Weaver1, S. McLaughlin1, 1Royal Bournemouth Hospital, Gastroenterology, Bournemouth, United Kingdom

P444

Successful allogeneic haematopoietic stem cell transplantation (HSCT) for refractory Paediatric Crohn's Disease without an identifiable genetic mutation - A case report

Authors:

A. Chebar Lozinsky*, B. Huggett, S. Sider, S. Chadokufa, J. Kammermeier, M. Elawad, F. Kiparissi, N. Shah

Great Ormond Street Hospital, Paediatric Gastroenterology, London, United Kingdom

P445.

Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy

Authors:

R. Monterubbianesi1, A. Aratari2, A. Armuzzi3, M. Daperno4, L. Biancone5, M. Cappello6, V. Annese7, G. Riegler8, A. Orlando9, A. Viscido10, G.M. Meucci11, A. Gasbarrini3, L. Guidi3, A. Lavagna4, R. Sostegni4, S. Onali5, C. Papi2, A. Kohn1, 1A.O.San Camillo Forlanini, Gastroenterology Unit, Rome, Italy, 2A.O.San Filippo Neri, Gastroenterology and Hepatology Unit, Rome, Italy, 3Columbus-Gemelli Hospital, IBD Unit, Rome, Italy, 4AO Ordine Mauriziano, Gastroenterology Division, Turin, Italy, 5Tor Vergata University, Internal Medicine, Rome, Italy, 6University of Palermo, Gastroenterology Section, Palermo, Italy, 7A.O. Careggi, Gastroenterology Division, Florence, Italy, 8University of Naples, Gastroenterology Unit, Naples, Italy, 9AO Villa Sofia-Cervello, Internal Medicine, Palermo, Italy, 10University of L'Aquila, Internal Medicine, L'Aquila, Italy, 11S. Giuseppe Hospital, Gastroenterology Unit, Milan, Italy

P445. Interleukin 19 gene polymorphisms in patients with ulcerative colitis
P445. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis
Authors:

M. Kawai1, Y. Yokoyama1, K. Fukunaga1, T. Ogawa1, K. Kamikozuru1, K. Nagase1, K. Tozawa1, N. Hida1, T. Matsumoto1, 1Hyogo College of Medicine, Department of Lower Gastroenterology, Nishinomiya, Japan

P445

Significance of non-alchoholic fatty liver disease in patients with Crohn's disease.

Authors:

S. Sagami*

Hiroshima University,, Department of Medicine and Molecular Science,, Hiroshima, Japan

P446.

Infliximab is an effective induction therapy in children with perianal fistulizing Crohn's disease

Authors:

A. Wegner, M. Dadalski, J. Kierkus, Children's Memorial Health Institute, Gastroenterology, Hepatology and Feeding Disorders, Warsaw, Poland

P446. Long term outcome of azathioprine therapy in 353 consecutive IBD patients
Authors:

H. Johnson1, K. Smith2, N. Jarrett1, S. McLaughlin1, S. Weaver1, 1Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom, 2Yeovil District Hospital, Department of Gastroenterology, Yeovil, United Kingdom

P446. Transcriptomic alterations in drug metabolism and steroid hormone biosynthesis in Crohn's disease patients
P447.

Infliximab in the treatment of moderate-to-severe ulcerative colitis: Results of a large multicenter Italian survey

Authors:

M. Cappello1, M. Mazza1, G. Costantino2, W. Fries2, A.C. Privitera3, M. Mastronardi4, F. Bossa5, A. Rispo6, F. Castiglione6, A. Lauria7, N. Buccianti8, R. Marasco9, L. Grossi10, M.B. Principi11, 1University of Palermo, Gastroenterology Section, DiBiMis, Palermo, Italy, 2University of Messina, Dipartimento di Medicina Interna e Terapia Medica, Messina, Italy, 3Ospedale Cannizzaro, Catania, Azienda Ospedaliera per l'Emergenza, Catania, Italy, 4IRCCS, Castellana Grotte (BA), UOC Gastroenterologia ed Endoscopia Digestiva, Castellana Grotte (BA), Italy, 5Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Gastroenterologia, S. Giovanni Rotondo (FG), Italy, 6Università Federico II, Napoli, Gastroenterologia, Napoli, Italy, 7A. O. Bianchi-Melacrino-Morelli, Reggio Calabria, Gastroenterologia e Endoscopia Digestiva, Reggio Calabria, Italy, 8A.O.S. Carlo, Potenza, U.O.C. di Medicina Interna, Potenza, Italy, 9Policlinico Catanzaro, UOC Gastroenterologia, Catanzaro, Italy, 10Ospedale Spirito Santo, Pescara, Fisiopatologia Digestiva, Pescara, Italy, 11Policlinico, Bari, Gastroenterologia, Bari, Italy

P447. Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis
Authors:

N. Viazis1, M. Giakoumis1, J. Anastasiou1, K. Katopodi1, G. Kechagias1, G. Tribonias1, D. Karamanolis1, 1Evangelismos Hospital, 2nd Department of Gastroenterology, Athens, Greece

P447. Transcriptomic profile in Crohn's disease with early post-surgical recurrence shows T and B cell polarisation